Capsule Endoscopy

Number: 0588

Policy

Aetna considers capsule endoscopy (e.g., Endocapsule) medically necessary for the following indications:

1. For evaluation of locoregional carcinoid tumors of the small bowel in persons with carcinoid syndrome; or
2. For evaluation of persons with celiac disease with a positive serology who are unable to undergo esophagogastroduodenoscopy (EGD) (e.g., medically unstable, presence of known or suspected perforated viscus) with biopsy; or
3. For re-evaluation of persons with celiac disease who remain symptomatic despite treatment and there is no suspected or confirmed gastro-intestinal (GI) obstruction, stricture, or fistulae; or
4. For initial diagnosis in persons with suspected Crohn's disease (abdominal pain or diarrhea, plus 1 or more signs of inflammation (e.g., fever, elevated white blood cell count, elevated erythrocyte sedimentation rate, elevated C reactive protein, or bleeding) without evidence of disease on conventional diagnostic tests, including small-bowel follow-through or abdominal CT scan/CT enterography and upper and lower endoscopy (esophago-gastro-duodenoscopy (EGD) and colonoscopy); or
5. For re-evaluation of persons with Crohn's disease who remain symptomatic despite treatment and there is no suspected or confirmed gastro-intestinal obstruction, stricture, or fistulae; or 
6. For investigating suspected small intestinal bleeding in persons with objective evidence of recurrent, obscure gastro-intestinal bleeding (e.g., persistent or recurrent iron-deficiency anemia and/or persisent or recurrent positive fecal occult blood test, or visible bleeding) who have had upper and lower gastro-intestinal endoscopies within the past 12 months (EGD and colonoscopy) that have failed to identify a bleeding source; or
7. For surveillance of small intestinal tumors in persons with Lynch syndrome, Peutz-Jeghers syndrome and other polyposis syndromes affecting the small bowel; or 
8. For screening or surveillance of esophageal varices in cirrhotic persons with significantly compromised liver function (i.e., Child-Pugh score of Class B or greater) or other situations where a standard upper endoscopy with sedation or anesthesia is contraindicated.

Capsule endoscopy is contraindicated and considered experimental and investigational under the following conditions:

• In persons with known or suspected GI obstruction, strictures, or fistulas based on the clinical picture or pre-procedure testing and profile
• In persons with cardiac pacemakers or other implanted electro-medical devices
• In persons with dysphagia or other swallowing disorders.

Aetna considers capsule endoscopy of the intestine experimental and investigational for evaluating abdominal pain because of insufficient evidence in the peer-reviewed literature unless one or more of the above-listed criteria are met.

Aetna considers capsule endoscopy experimental and investigational for all other indications including the following because of insufficient evidence in the peer-reviewed literature (not an all-inclusive list):

• Repeat use to verify the effectiveness of surgery
• Use as a screening test (other than esophageal varices)
• Use as an initial test in diagnosing GI bleeding
• Use in colorectal cancer screening
• Use in confirming pathology identified by other diagnostic means
• Use in detecting gastric varices
• Use in detecting hookworms
• Use in diagnosng of Takayasu’s arteritis
• Use in evaluating diseases involving the esophagus other than esophageal varices
• Use in evaluating intussusception
• Use in evaluating mucosal inflammation in ulcerative colitis
• Use in evaluating the colon
• Use in evaluating the stomach
• Use in follow-up of persons with known small bowel disease other than Crohn's disease
• Use in investigating duodenal lymphocytosis, small bowel neoplasm, or suspected irritable bowel syndrome
• Use in planning for radiation therapy
• Use in staging portal hypertensive gastropathy

Aetna considers the Agile patency capsule experimental and investigational for evaluating patency of the gastrointestinal tract before wireless capsule endoscopy, and for all other indications because of insufficient evidence in the peer-reviewed literature.

Background

Capsule endoscopy (CE), also known as wireless capsule endoscopy or video capsule endoscopy, is a noninvasive, diagnostic procedure that is designed to visualize the esophagus, stomach, small bowel or colon. To perform this procedure, a small digestible capsule (approximately the size of a large vitamin) containing a video camera and a light source is swallowed. The camera takes multiple pictures per second and sends electronic signals wirelessly to a data recorder worn around the individual’s waist. The data is then downloaded into a computer program that captures the images to be analyzed by a physician. The capsule is typically excreted naturally by the body within eight to 72 hours after ingestion.

Currently, capsule endoscopy is only utilized for diagnostic purposes; individuals who require a biopsy or therapeutic intervention must then undergo a conventional endoscopic procedure. Examples of FDA approved CE devices include, but may not be limited to:

• PillCam COLON 2 is intended for use only in individuals who had an incomplete optical colonoscopy with adequate preparation and a complete evaluation of the colon was not technically possible.)
• PillCam ESO is intended for the visualization of the esophageal mucosa to detect abnormalities such as gastroesophageal reflux disease (GERD), Barrett’s esophagus or varices.
• PillCam Express is a disposable device that is purportedly for the transendoscopic delivery of the PillCam SB device in individuals who are unable to ingest the PillCam capsule or are known to have slow gastric emptying time.
• PillCam patency system is Intended for use as an accessory to capsule endoscopy to verify small bowel patency or suspected strictures.
• Pill Cam SB 2 and 3 and the Olympus small intestine endoscope capsule are intended for the visualization of the small intestinal mucosa.
• PillCam UGI capsule endoscopy system is intended for visualization of the upper gastrointestinal tract (esophagus, stomach, duodenum) in hemodynamically stable individuals who are at least 18 years of age.

According to guidelines from the American Gastroenterological Association (2001), the standard for diagnosing the source of small intestinal bleeding is push enteroscopy, in which a 4-foot long tube out-fitted with a small video camera is inserted down the esophagus, through the stomach and into the first third of the small intestine. In many cases, a definitive diagnosis cannot be made because the imaging tools cannot reach far enough into the digestive tract to find the problem. Radiologic examination of the small bowel with barium (enteroclysis) may be uncomfortable, time-consuming, and is incapable of detecting completely flat lesions of the small intestine (e.g., arteriovenous malformations).

In August 2001, the U. S. Food and Drug Administration (FDA) cleared for marketing a swallowable capsule containing a small camera that snaps pictures twice a second as it passes through the small intestine. The FDA classified the capsule, called the Given Diagnostic Imaging System (Given Imaging Ltd., Yoqneam, Israel), as a Class II device that is subject only to general regulatory controls. The capsule, marketed as the PillCam SB (previously marketed as M2A^™), has a clear end that allows the camera to view the lining of the small intestine. In addition to the camera, the wireless capsule, about the size of a large vitamin pill, contains a lighting system and a transmitter that will send images from inside the intestine to video monitors, allowing doctors to detect sources of bleeding in the small intestine. FDA cleared the device for use along with, not as a replacement for, other endoscopic and radiological evaluations of the small intestine. The capsule was not studied in the large intestine.

When swallowed, the device travels down the digestive tract at about the same speed as food, propelled by peristalsis, and takes 2 to 3 hours to pass through. Once the device reaches the colon, things slow down, and the disposable device is eliminated like any solid waste within a few days.

The downside to this technology is that the images may not match fiber-optic endoscopes for detail, and concerns have been raised that the camera's view may be obscured by bubbly saliva or green bile. The capsule cannot be stopped or steered to collect close-up details of the small intestine's millions of interior wrinkles where ailments often occur. Nor is it fitted with surgical tools like a conventional endoscope to take biopsies or treat bleeding lesions or remove polyps. If a lesion requiring invasive therapy is found on capsule endoscopy, then the patient will need to undergo surgery with intra-operative endoscopy. In addition, if an abnormality is seen on capsule endoscopy, there is no good way to define its location within the small intestine. Fleischer (2002) has noted that, with capsule endoscopy, “the pylorus is usually seen, and in many patients the ileocecal valve can be demonstrated, but apart from a rough estimate linked to 'time beyond the pylorus' or 'time in front of the ileocecal valve', specific localization is not possible.”

By contrast, push enteroscopy has the advantages of being able to perform biopsies and offer therapy. If capsule endoscopy is performed without a prior push enteroscopy, a push enteroscopy will still need to be performed in most cases since a negative capsule endoscopy may not exclude a lesion, and a lesion observed on capsule examination may be within reach of the enteroscope (Faigel and Fennerty, 2002).

In a study submitted to the FDA, the Given Imaging Diagnostic System detected physical abnormalities in 12 of 20 patients with suspected small intestinal disorders, while push enteroscopy detected physical abnormalities in 7 of 20 patients. All patients included in the trial had previously undergone gastrointestinal endoscopies and radiological procedures to identify the source of their small intestinal disorders, without a conclusive diagnosis. In total, 14 lesions were detected in 13 of the 20 patients participating in the clinical trials using either the Given Imaging Diagnostic System, push enteroscopy or surgical techniques. The Given Imaging Diagnostic System detected 12 of the 14 lesions, while push enteroscopy detected 7 of 14. The investigators also noted that the Given system was able to identify sources of bleeding in 5 cases that were beyond the reach of the traditional enteroscope.

Costamagna et al (2002) compared the performance of capsule endoscopy to upper gastrointestinal barium radiography series with small bowel follow through in 20 patients, including 13 patients with obscure gastrointestinal bleeding, 3 patients with suspected Crohn's disease, 1 patient with suspected sarcoma recurrence, 1 patient with diarrhea, 1 patient with familial adenomatous polyposis, and 1 patient with small intestine polyposis. The rates of a “diagnostic” test were higher for capsule endoscopy (45 %) than for barium examination (27 %), although no test was performed to determine whether this difference was statistically significant. Among the subset of 13 patients with obscure gastrointestinal bleeding, the rates of a diagnostic test were statistically significantly higher for capsule endoscopy (30 %) than for the barium study (5 %); however, the study does not describe how this statistical analysis was performed.

This study has been criticized on several grounds (see, e.g., Faigel and Fennerty, 2002). First, the small heterogenous population included in this study makes it difficult to discern the role of this new technology in clinical practice. Second, the study does not evaluate all relevant competing technologies; specifically, the study does not examine how capsule endoscopy performs in comparison to enteroclysis or push enteroscopy; the latter may have been a more appropriate endoscopic standard for comparison. Third, the study chose to report on “diagnostic yield” because no gold standard study was performed; diagnostic yield cannot differentiate true from false positives or true from false negatives. Two studies reported higher diagnostic yields with capsule endoscopy than push enteroscopy in small groups of patients with chronic gastrointestinal bleeding. Lewis and Swain (2002) reported on the results of a pilot study of capsule endoscopy and push enteroscopy in 21 adult patients with obscure gastrointestinal bleeding whose source was not uncovered with esophago-gastro-duodenoscopy (EGD), colonoscopy or small bowel follow through. Capsule endoscopy was able to identify a bleeding source in 11 patients (55 %), whereas push enteroscopy was able to identify a bleeding source in 6 patients (30 %) (p = 0.0625). In Germany, Ell et al (2002) reported on a comparison of capsule endoscopy to push enteroscopy in 32 patients with chronic gastrointestinal bleeding. Push enteroscopy revealed definite bleeding sites in 9 patients (28 %), including angiodysplasia in 7 patients, small intestine cancer in 1 patient, and lymphoma in 1 patient. Capsule endoscopy detected definite bleeding sites in 21 patients (66 %), including angiodysplasia in 17 patients, malignant stenoses in 2 patients, and inflammatory small-intestine disease in 2 patients. Questionable bleeding sources were seen on push enteroscopy in 3 additional patients (9 %) and using capsule endoscopy in an additional 7 patients (22 %).

Much of the clinical evidence on capsule endoscopy has been presented in the form of abstracts rather than as peer-reviewed published clinical studies. As no study has compared capsule endoscopy to surgical enteroscopy or some other reliable external criterion (i.e., gold standard), the sensitivity, specificity, and predictive values of capsule endoscopy are unknown. In addition, no study has reported on the effect of capsule endoscopy on resolution of bleeding or other relevant clinical outcomes.

In the acute setting, capsule endoscopy is not a substitute for tagged red cell scintigraphy or angiography, because capsule endoscopy takes 8 hours to complete with the results generally not available until the following day.

The BlueCross BlueShield Technology Evaluation Center (2003) evaluated the evidence supporting the use of capsule endoscopy for diseases of the small intestine other than obscure gastrointestinal bleeding. The assessment identified no randomized controlled clinical studies of capsule endoscopy for these indications. The assessment identified 3 published studies (Fireman et al, 2003; Herrerias et al, 2003; Eliakim et al, 2003), involving a total of 58 patients, that prospectively examined the use of capsule endoscopy for initial diagnosis of suspected Crohn's disease when all conventional diagnostic tests, including small-bowel follow-through, have failed to reveal bowel lesions suggestive of Crohn's disease. An additional 41 patients were included in 2 abstract reports and case reports (Sant'anna et al, 2003; Bloom et al, 2003; Costamanga et al, 2003; Chong et al, 2003; Liangpunsakul et al, 2003). The assessment concluded that “[t]hese studies provide consistent evidence that wireless capsule endoscopy may demonstrate small-bowel lesions suggestive of Crohn's disease in a significant proportion of patients ranging from 43 to 71 % when all other conventional tests have been negative. Furthermore, patients in these studies diagnosed with Crohn's disease by wireless capsule endoscopy were reported to improve after treatment for Crohn's disease, which represents an improvement in health outcomes.”

The assessment did not find sufficient evidence to support the use of capsule endoscopy for other indications, including initial diagnosis of irritable bowel syndrome, celiac sprue, small bowel neoplasm, or intestinal polyposis syndrome, or follow-up of persons with known small bowel diseases. The assessment identified 1 published study, involving 20 patients, that examined the diagnostic yield of capsule endoscopy in persons with suspected irritable bowel syndrome, but none of the subjects had significant findings on capsule endoscopy (Bardan, 2003). The assessment found that the evidence for all remaining indications was limited to abstracts and case reports.

An assessment by the National Institute for Clinical Excellence (2004) found adequate evidence to support the use of capsule endoscopy, but that “[c]linicians should consider the use of other investigations prior to wireless capsule endoscopy …” The assessment noted that the main indication for this procedure is obscure gastrointestinal bleeding, which is defined as bleeding of unknown origin that persists or recurs after a negative initial endoscopy. The assessment noted that capsule endoscopy has also been used in the diagnosis and evaluation of Crohn's disease. The assessment noted that some studies have reported a higher diagnostic yield (proportion of patients identified with an apparent abnormality) than the comparator test. The assessment noted, however, in most cases, patients had undergone extensive prior investigations, which would be likely to decrease the apparent diagnostic yield for the comparator procedures. The assessment stated that “[i]t was not possible to determine the relative diagnostic performance (ability to detect correctly both the presence and absence of disease) of wireless capsule endoscopy compared with alternative conventional diagnostic tests” in the assessment of obscure gastrointestinal bleeding. Similarly, with respect to diagnosis of Crohn's disease, the assessment found that the available evidence “is not of sufficient quantity and quality to determine the relative diagnostic performance of wireless capsule endoscopy compared with alternative conventional diagnostic tests in diagnosing unselected patients with suspected Crohn's disease.”

The American Gastroenterological Association position statement on obscure gastro-intestinal bleeding (OGIB) (Raju et al, 2007) stated that patients with occult gastro-intestinal (GI) blood loss and iron deficiency anemia and negative workup on EGD and colonoscopy need comprehensive evaluation, including capsule endoscopy to identify an intestinal bleeding lesion.

An assessment by the Belgian Health Care Knowledge Center (Poelmans et al, 2006) recommended capsule endoscopy in patients with obscure GI bleeding “when a previous ileocolonoscopy and esophagogastroduodenoscopy were negative.” The assessment found that, “[a]t present, the available evidence is not of sufficient quantity and quality to determine the relative diagnostic performance of CE compared with alternative conventional diagnostic tests in diagnosing patients with CD [Crohn's disease], intestinal polyposis and celiac disease. No conclusions can be made as to whether CE is an effective alternative to other tests. Further research is warranted to determine the place of CE in the management algorithm of OGIB [obscure GI bleeding] and on other potential indications for CE such as CD, intestinal polyposis and celiac disease.”

The main limitations of capsule endoscopy in the assessment of small bowel Crohn’s disease are the lack of uniform criteria for diagnosing Crohn’s disease, inability to allow for tissue acquisition or therapeutic intervention, and the risk for capsule retention. Capsule retention in Crohn’s disease patients resulting from underlying small bowel strictures is a major concern. Retained capsules may require surgery in patients that may otherwise have not required surgery. A preingestion radiologic study (computed tomography [CT] or small bowel follow through) is recommended because asymptomatic strictures occur in a substantial proportion of patients with Crohn’s disease. Patients with obstructive symptoms or with endoscopic and radiographic evidence of small bowel narrowing in the setting of Crohn’s disease should not undergo capsule endoscopy.

The American College of Radiology appropriateness criteria for Crohn’s disease (2008) state that wireless capsule endoscopy is likely to play an increasing role in the early diagnosis of Crohn’s disease. However, because of a 5 percent incidence of capsule retention proximal to unsuspected strictures, imaging studies, such as small-bowel follow through, are likely to remain an important screening tool prior to capsule endoscopy examinations. The guidelines state that CT is the initial imaging technique of choice in suspected Crohn’s disease complications, and shows considerable promise in initial diagnosis and estimation of disease severity. Other guidelines similarly recommend reserving capsule endoscopy to patients with suspected Crohn’s disease and negative workup, where strictures have been excluded (see, e.g., World Gastroenterology Organization Global Guidelines, 2009; British Society of Gastroenterology, 2008).  There is a lack of prospective studies demonstrating that use of capsule endoscopy for followup of persons with established Crohn’s disease alters management such that clinical outcomes are improved. Evidence has focused on diagnostic yield. A retrospective study by Long, et al. (2011) reported on changes in management after capsule endoscopy; however, the study does not report on whether clinical outcomes are improved. The European Consensus Statement that was cited states that capsule endoscopy “has a potential role” in assessment of mucosal healing after drug therapy.” It should be noted that this recommendation is based upon low quality evidence, evidence level 4: “Case–control study, poor or nonindependent reference standard”; and a grade C recommendation based upon these studies. The guidelines do not endorse a routine role for capsule endoscopy for followup; rather capsule endoscopy “should only be considered if ileocolonoscopy is contraindicated or unsuccessful,” a recommendation that is based upon limited evidence.

Capsule endoscopy has been used in detecting carcinoid tumors of the small intestine. Guidelines from the National Comprehensive Cancer Network (NCCN, 2008) recommend the use of an Octreoscan for persons who present with carcinoid syndrome to determine tumor location and extent. Appendiceal tumors require abdominopelvic CT. Bronchoscopy, upper gastrointestinal barium swallow with small bowel follow through as indicated, colonoscopy and gastroscopy as indicated to identify the primary site. An MRI of the lung, mediastinum and head, and a CT scan of the chest, abdomen and pelvis may also be helpful, depending on the possible site. For work-up of carcinoid tumors of the small bowel, the NCCN guidelines recommend an initial evaluation with an Octreoscan and abdominopelvic CT scan.  For persons with locoregional disease, additional workup is recommended with a GI series with small bowel follow-through as indicated. Enteroclysis or capsule endoscopy are considered optional tests for work-up of locoregional disease of the small bowel.

Capsule endoscopy may also be useful for identifying celiac disease of the small intestine in persons with positive serologies where previous intestinal biopsies have been negative. Rondonotti et al (2007) found capsule endoscopy comparable to EGD for the diagnosis of celiac disease when there are overt villous changes. Consecutive patients with signs and symptoms suggestive of celiac disease and positive anti-gliadin and/or anti-endomysial and/or anti-tissue transglutaminase antibodies underwent upper gastrointestinal endoscopy and capsule endoscopy. Duodenal biopsies were classified according to modified Marsh's criteria. Capsule findings were evaluated for the presence of lesions compatible with celiac disease (scalloping of duodenal folds, fissures, flat mucosa, and mosaic appearance). Duodenal histology was normal in 11 and compatible with celiac disease in 32 of 43 patients studied. Using duodenal histology as the gold standard, the performance characteristics of capsule endoscopy for the diagnosis of celiac disease were: sensitivity 87.5 % (95 % confidence interval [CI]: 76.1 to 98.9 %), specificity 90.9 % (95 % CI: 81.0 to 100 %), positive predictive value 96.5 % (95 % CI: 90.1 to 100 %), negative predictive value 71.4 % (95 % CI:  55.8 to 87 %), positive and negative likelihood ratios 9.6 and 0.14, respectively. Eighteen patients had mucosal changes extending beyond the duodenum, involving the entire small bowel in three. These patients tended to have more severe symptoms, but the difference was not statistically significant. Interobserver agreement for the diagnosis of celiac disease by capsule endoscopy ranged between 79.2 and 94.4 %; kappa values ranged between 0.56 and 0.87. The authors concluded that capsule endoscopy shows good sensitivity and excellent specificity for the detection of villous atrophy in patients with suspected celiac disease.

Capsule endoscopy can be used for surveillance in persons with Peutz-Jeghers syndrome and other intestinal polyposis syndromes. An assessment of capsule endoscopy for the surveillance of persons with Peutz-Jeghers syndrome for the Australian Medical Service Advisory Committee (MSAC, 2007) recommended capsule endoscopy, performed no more than once in any two year period, for small bowel surveillance in patients diagnosed with Peutz-Jeghers syndrome. The assessment concluded that capsule endoscopy is a safe, well-tolerated procedure compared with small bowel surveillance by barium follow-through. The assessment stated that the small body of literature published on the clinical effectiveness of capsule endoscopy in small bowel surveillance of Peutz-Jeghers syndrome "limits the scope of analysis that can be performed to assess this technology." The MSAC found, however, that capsule endoscopy has changed management of persons with Peutz-Jeghers syndrome in situations where x-ray examinations have produced false negative results. The MSAC also found that capsule endoscopy for small bowel surveillance of Peutz-Jeghers syndrome is likely to be as effective and as cost-effective as small intestine x-ray.

Capsule endoscopy is also being investigated for detecting esophageal pathology. Given Imaging Ltd. (Yoqneam, Israel) received marketing clearance from the FDA in November 2004 for its Given Diagnostic System with PillCam ESO video capsule for imaging the esophagus. The PillCam ESO is being marketed for the diagnosis and evaluation of diseases of the esophagus such as gastroesophageal reflux disease (GERD), erosive esophagitis and Barrett's esophagus, a pre-cancerous condition. The FDA classified the PillCam ESO video capsule as a Class II device that is subject only to general regulatory controls.

The PillCam ESO is the same size as the PillCam SB (11 x 26 mm); however, miniaturization of electronics has enabled the PillCam ESO capsule to include 2 video cameras, 1 at each end of the capsule. Each imager captures 2 images per second, totaling 4 images per second. The esophageal transit time of the capsule is brief (less than 5 seconds) when patients ingest the capsule with water in the upright position. The transit time may be lengthened by having the patient ingest the capsule lying horizontally, which may allow visualization of the squamocolumnar junction.

In a feasibility study, Eliakim et al (2004) compared the PillCam ESO to conventional upper endoscopy as the gold standard for detection of esophageal pathologies in patients with suspected disorders of the esophagus (n = 17). Esophageal pathology was found in 12 of the patients by conventional upper endoscopy and with the PillCam ESO. An additional pathology that was found with the PillCam ESO was considered a false-positive. The authors concluded that this pilot study provides evidence that the esophageal capsule is an accurate, convenient, safe and well-tolerated method to screen patients for significant esophageal disorders; however, the authors stated that further, large-scale studies are necessary to fully assess this diagnostic tool.

A multi-center prospective study by the same investigator group, Eliakim et al (2005) compared the PillCam ESO to conventional upper endoscopy in patients with chronic GERD (n =  93) and Barrett's esophagus (n = 13). The PillCam ESO identified esophageal abnormalities in 61 of the 66 patients with positive esophageal findings (sensitivity, 92 %; specificity, 95 %). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the PillCam ESO for Barrett esophagus were 97 %, 99 %, 97 %, and 99 %, respectively, and for esophagitis 89 %, 99 %, 97 %, and 94 %, respectively. The authors reported no adverse events related to the PillCamESO during the 2-week follow-up period and concluded that it is a convenient and sensitive method for visualization of esophageal mucosal pathology and may provide an effective method to evaluate patients for esophageal disease. The authors reported that future generations of esophageal capsules with higher frame speed are in clinical trials.

The PillCam ESO is also being investigated for use in evaluating patients with esophageal varices.  Potential advantages of capsule endoscopy over EGD is the ability to avoid sedation in patients with liver cirrhosis, and the ability to perform capsule endoscopy during the office visit.  In a pilot study of 32 patients with cirrhosis, the PillCam ESO was compared with EGD in detecting esophageal varices and portal hypertensive gastropathy. A total of 23 patients had esophageal varices at both EGD and PillCam ESO evaluation (Eisen et al, 2006). The overall concordance between PillCam ESO and EGD was 96.9 % for the diagnosis of esophageal varices and 90.6 % for portal hypertensive gastropathy. 

De Franchis et al (2007) reported on a multi-center clinical trial comparing capsule endoscopy to EGD in detecting esophageal varices. Patients who were undergoing clinically indicated EGD for screening or surveillance of esophageal varices were asked to undergo capsule endoscopy prior to the EGD. EGD was performed within 48 hours of capsule endoscopy. A second investigator read each capsule endoscopy study, blinded to patient history and EGD results. A total of 285 patients underwent capsule endoscopy and EGD, 61 % of whom underwent the procedures for screening, and the remainder for surveillance of known esophageal varices. Sensitivity, specificity, positive predictive value and negative predictive value for capsule endoscopy compared to EGD were 86.7 %, 88.4 %, 92.9 %, and 79.1 %, respectively. Overall agreement was 87.3 % (95 % CI: 83 % to 91 %). There was complete agreement on varices grade in 82 % of cases. In 3 cases, capsule endoscopy did not detect esophageal varices that were considered medium/large on EGD, and EGD did not detect 1 case of medium esophageal varices seen on capsule endoscopy. In differentiating between 2 patient management alternatives (i.e., large varices which requires treatment and small varices or no varices which requires monitoring), sensitivity, specificity, positive predictive value and negative predictive value for capsule endoscopy compared to EGD were 84.6 %, 96.1 %, 89.2 % and 94.3 %, respectively. The overall agreement of treatment decisions based on esophageal varices size was 93 %.

Commenting on the study by de Franchis et al, Zaman (2008) stated that although the overall performance of esophageal capsule endoscopy was good, the study’s primary endpoint was not met -- capsule endoscopy was not equivalent to EGD for detecting varices. Zaman concluded that EGD should therefore continue to be the first-line modality for this application. However, capsule endoscopy should be considered an alternative modality if EGD is contraindicated because of concerns regarding safety or tolerance.

Lapalus and associates (2006) reported on a study comparing EGD and PillCam ESO in evaluating portal hypertension in 21 patients with cirrhosis. The PillCam ESO accurately assessed the presence or absence of esophageal varices in 17 of 20 patients (85 %). The 3 patients in whom there was a discrepancy between the 2 procedures were diagnosed with grade 1 varices on EGD and no varices on esophageal capsule endoscopy. The sensitivity of capsule endoscopy for detecting esophageal varices in comparison with EGD as the gold standard was 81.25 % (13 of 16), with a 100 % positive predictive value, a specificity of 100 % (12 of 12), and a negative predictive value of 57.1 % (4 of 7). In evaluating the stomach, 1 patient presented with gastric varices that were diagnosed with both EGD and capsule endoscopy. Portal hypertension gastropathy was diagnosed with EGD in 16 of 21 patients and with capsule endoscopy in 13 of 20 patients. The 4 patients in whom there was a discrepancy were diagnosed as having gastropathy on EGD but not on capsule endoscopy in 3 cases, or as having gastropathy on capsule endoscopy but not on EGD in 1 case.

Rubin et al (2011) reported on a randomized controlled clinical trial that found that use of esophageal capsule endoscopy to risk stratify emergency room patients with upper gastrointestinal bleeding (UGIB) significantly reduced time to emergent EGD and therapeutic intervention. A total of 24 patients with a history of UGIB within 48 hours of admission to the ER were randomized to esophageal capsule endoscopy versus standard clinical assessment. Esophageal capsule endoscopy was read real-time at the bedside and later reviewed after download. Positive capule endoscopy findings included coffee grounds, blood clot, red blood, or a bleeding lesion. Capsule endoscopy positive patients underwent EGD within 6 hours. Control patients and capsule endoscopy negative patients underwent EGD within 24 hours. Seven of 12 patients were capsule endoscopy positive. All 7 had confirmatory stigmata at EGD. Of the 5 capsule endoscopy negative patients, 4 had no stigmata at EGD and 1 was not endoscoped due to comorbidities. The actual lesion was visualized at capsule endoscopy in 4 of 12 patients during live view and in an additional 2 patients after download (6/12). Time to endoscopy in the capsule endoscopy positive group was significantly shorter than control patients (2.5 versus 8.9 hours, p = 0.029). There was no mortality. Blood transfusion requirement and length of stay were not significantly different in the 2 groups. Bjorkman (2010) stated that this was a very small study that had multiple limitations, including the potential for missing duodenal lesions, given that the capsule reached the duodenum in only 7 patients (58 %). The commentator also noted that many positive findings of capsule endoscopy (active bleeding, coffee grounds, and clots) can be identified with simple gastric aspiration. Bjorkman (2010) stated that the cost-effectiveness of esophageal capsule endoscopy in this setting is unclear.

Guidelines on the prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis from the American Association for the Study of Liver Diseases states the frequency of surveillance endoscopies in patients with no or smal varices depends upon their natural history (Garcia-Tsao et al, 2007). Upper endoscopy should be performed once the diagnosis is established. In patients with compensated cirrhosis who have no varices on screening endoscopy, upper endoscopy should be repeated in 2 to 3 year intervals. In those who have small varices, upper endoscopy should be repeated in 1 to 2 years. In the presence of decompensated cirrhosis, upper endoscopy should be repeated at yearly intervals.

An assessment by the American Society for Gastrointestinal Endoscopy (ASGE, 2006) found “[t]o date there are limited published data on capsule endoscopy of the esophagus…These preliminary data show an excellent diagnostic yield in cases of erosive esophagitis, Barrett's esophagus, and esophageal varices.”

The American College of Gastroenterology (ACG) (1999) recommends that patients with long-standing GERD symptoms, particularly those 50 years of age and older, undergo an upper endoscopy for evaluating the mucosa for esophagitis. Approximately 20 % of U.S. adults have symptoms of GERD at least once a week; however, a subgroup of patients with GERD develops severe complications that include erosive esophagitis, stricture formation, Barrett's esophagus, and adenocarcinoma of the esophagus. The ACG state that “patients with chronic GERD symptoms are those most likely to have Barrett's esophagus and should undergo upper endoscopy.” ACG guidelines state that the diagnosis of Barrett's esophagus requires biopsy to determine whether intestinal metaplasia is present. Tissue acquisition can be performed during conventional endoscopy for biopsy.

Thus, capsule endoscopy cannot completely replace conventional endoscopy for the evaluation of diseases involving the esophagus and its clinical value as a screening technique for suspected Barrett's esophagus remains unclear. The clinical effectiveness of the PillCam ESO in screening GERD patients for suspected Barrett's esophagus to direct appropriate patients for endoscopic biopsy needs to be demonstrated by large-scale clinical trials published in the peer-reviewed medical literature.

In a prospective, multi-center, blinded study, Lin and colleagues (2007) evaluated the accuracy of esophageal capsule endoscopy (ECE) for the diagnosis of Barrett's esophagus. Major outcome measures included sensitivity, specificity, as well as positive and negative predictive values of ECE for Barrett's esophagus by using EGD results, with histological confirmation as the criterion standard. A total of 96 subjects were enrolled, of whom 90 (94 %) completed the study, including 66 screening and 24 surveillance patients. Esophageal capsule endoscopy was 67 % sensitive and 84 % specific for identifying Barrett's esophagus, diagnosing 14 of 21 cases of biopsy-confirmed Barrett's esophagus. Positive and negative predictive values were 22 % and 98 %, respectively (calculated for screening patients only). Sensitivity for short- and long-segment Barrett's esophagus was similar. The authors concluded that the findings of this study showed that ECE had only moderate sensitivity and specificity for identifying Barrett's esophagus. They noted that ECE in its present form is unsuitable as a primary screening tool for Barrett's esophagus; however, ECE may be used in patients unwilling to undergo EGD.

Johnson (2007) noted that the findings by Lin et al (2007) are contradictory to the favorable results from the study by Eliakim et al (2005). This discrepancy is surprising because some earlier studies had been carried out with capsules that captured only 4 frames per second rather than the 14 frames per second captured by the capsule that was used in the present study. In the validation study, experts who were aware of both the endoscopy and the capsule findings adjudicated final diagnoses; as the current study did not include this protocol, its results could reflect "real-world" use more accurately. Although the convenience, safety, and patients’ tolerance of CE make it an attractive tool for esophageal imaging, at present, this device probably cannot be relied on for the one-time screening to exclude Barrett's esophagus in patients with chronic GERD.

Johnson (2008) commented that 2 recent studies (citing Sharma et al, 2008; Quershi et al, 2008) have demonstrated that esophageal capsule endoscopy is unreliable for detection of BE and has high interobserver variability, particularly with respect to short -segment BE (SSBE). Johnson (2008) concluded that these studies demonstrate that esophageal capsule endoscopy in its current form is not an adequate tool for screening for BE.

Sharma et al (2008) reported on a prospective trial involving 100 patients who had GERD symptoms or were under surveillance for BE. All patients underwent esophageal capsule endoscopy, followed by standard upper endoscopy, which was considered the gold standard. The esophageal capsule endoscopy findings were evaluated by investigators who were blinded to the endoscopic findings. BE was confirmed histologically in 45 of the 94 patients who completed the study. Esophageal capsule endoscopy demonstrated a sensitivity of 78 %, a specificity of 75 %, a positive predictive value of 74 %, and a negative predictive value of 79 %. The corresponding accuracy for diagnosing erosive esophagitis was 50 %, 90 %, 56 %, and 88 %, respectively.

Quershi et al (2008) reported on a prospective trial involving patients with short-segment BE (SSBE). A total of 20 patients with biopsy-proven SSBE underwent capsule endoscopy of the esophagus; images were subsequently reviewed by 2 experts who had no knowledge about the purpose of the study. Eighteen patients completed the study. BE was identified or suspected in 44 % of these patients by 1 observer but in only 16 % by the second observer. The Z-line was identified in all 18 patients by both observers, but there was agreement in only 6 as to whether it was normal or irregular.

American College of Gastroenterology guidelines do not support the use of esophageal capsule endoscopy for Barrett's esophagus (Wang et al, 2008).  

Capsule endoscopy has not been proven to be of value in detecting conditions in the colon. The major technical limitations of capsule colonoscopy are its requirement for highly effective bowel preparation and the limited frame speed of the current version. The colon is not well visualized with capsule endoscopy because stool obscures the visualization of the colonic mucosa. Visualization of the colon is more difficult than the small intestine because of its slower transit time and larger diameter; it is possible for the camera to miss suspicious areas of the colon simply by being pointed in the wrong direction. An American Cancer Society position statement (Levin et al, 2003) has concluded that there is no evidence to support the use of capsule endoscopy for detecting colorectal polyps or cancers.

Rex (2008) commented that capsule colonoscopy is similar to computed tomography colonography in having required polyp-size thresholds for referral for polypectomy. Rex stated that, from a cost-effectiveness standpoint, capsule colonoscopy is dominated by colonoscopy when equal adherence is assumed (citing Hassan et al, 2008). For capsule colonoscopy, improvements in adherence could overcome deficiencies in effectiveness (Rex, 2008). However, there currently is no good evidence of improved compliance with capsule colonoscopy. Thus, although capsule colonoscopy could improve adherence, actual demonstrations of whether and how much improvement could be expected are needed.

The Canadian Agency for Drugs and Technologies in Health (CADTH)'s report on capsule colonoscopy/PillCam Colon (Tran, 2007) stated that there is limited evidence on the use of this technology in imaging the colon. Two small, methodologically flawed pilot studies found that for patients with positive findings (i.e., abnormalities detected), the rates of detection with the PillCam Colon capsule were similar to those obtained with conventional colonoscopy. Larger, multi-center trials that compare CE with colonoscopy are needed. The evidence to support the use of CE in screening for colorectal cancer is also lacking.

In a prospective, multi-center study, Van Gossum and colleagues (2009) compared CE with optical colonoscopy (the standard for comparison) in a cohort of patients with known or suspected colonic disease for the detection of colorectal polyps or cancer. Patients underwent an adapted colon preparation, and colon cleanliness was graded from poor to excellent. These investigators computed the sensitivity and specificity of CE for polyps, advanced adenoma, and cancer. A total of 328 patients (mean age of 58.6 years) were included in the study. The capsule was excreted within 10 hours after ingestion and before the end of the lifetime of the battery in 92.8 % of the patients. The sensitivity and specificity of CE for detecting polyps that were 6 mm in size or bigger were 64 % (95 % CI: 59 to 72) and 84 % (95 % CI: 81 to 87), respectively, and for detecting advanced adenoma, the sensitivity and specificity were 73 % (95 % CI: 61 to 83) and 79 % (95 % CI: 77 to 81), respectively. Of 19 cancers detected by colonoscopy, 14 were detected by CE (sensitivity, 74 %; 95 % CI: 52 to 88). For all lesions, the sensitivity of CE was higher in patients with good or excellent colon cleanliness than in those with fair or poor colon cleanliness. Mild-to-moderate adverse events were reported in 26 patients (7.9 %) and were mostly related to the colon preparation. The authors concluded that the use of CE of the colon allows visualization of the colonic mucosa in most patients, but its sensitivity for detecting colonic lesions is low as compared with the use of optical colonoscopy.

In an editorial that accompanied the afore-mentioned article, Bretthauer (2009) stated that colonoscopy, CT colonography and colon CE (CCE) should be tested in randomized, comparative trials that allow valid and precise quantification of their effect on colorectal cancer (CRC) incidence and mortality.

Sieg et al (2009) stated that CRC screening with colonoscopy was introduced into the National Cancer Prevention Program in Germany in 2002. As compliance for screening is low (around 3 % per year), CCE could be an alternative approach. In this study, feasibility and performance of CCE were evaluated in comparison with colonoscopy in ambulatory patients with special attention to a short colon transit time. Colon CE was prospectively tested in ambulatory patients enrolled for colonoscopy who presented for screening or with positive fecal occult blood test. Study subjects underwent colon preparation and ingested the capsule in the morning. Colonoscopy was performed after excretion of the capsule. Colonoscopy and CCE were performed by independent physicians who were blinded to the results. A total of 38 patients were included. One patient was excluded because the capsule remained in the stomach during the entire period of examination. Another patient had limited time and the procedure had to be stopped when the capsule was still in the transverse colon. Thus, these investigators reported the results of 36 patients (30 men and 6 women; mean age of 56 years, range of 23 to 73 years) who successfully completed CCE and the conventional colonoscopy examination. The capsule was excreted within 6 hours in 84 % of the patients (median transit time 4.5 hours). If oral sodium phosphate was excluded from the preparation, the colon transit time increased to a median of 8.25 hours. In total, 7 of 11 small polyps (less than 6 mm) detected by colonoscopy were identified by CCE. One small polyp detected by CCE was not identified by colonoscopy. In this series, no large polyps were found. One CRC was detected by both methods. The mean rates of colon cleanliness (range from 1 = excellent to 4 = poor) in the cecum (2.1), transverse colon (1.6), and in the descending colon (1.5) were significantly better than in the rectosigmoid colon (2.6), and the overall mean rate during colonoscopy was significantly better than during CCE. No adverse effects occurred. The authors concluded that CCE appears to be a promising new modality for colonic evaluation and may increase compliance with CRC screening. To achieve a short colon transit time, sodium phosphate seems to be a necessary adjunct during preparation. The short transit time is a prerequisite to abandon the delay mode of the capsule. With an undelayed PillCam COLON capsule, a "pan-enteric" examination of the gastrointestinal tract would be possible. They stated that further studies are needed to improve the cleanliness, especially in the rectum and to evaluate the method as a potential screening tool.

In a retrospective case series, Triantafyllou and colleagues (2009) evaluated if PillCam colon capsule (PCC) endoscopy can complete colon examination after failure of conventional colonoscopy to visualize the cecum. By using PCC, these investigators studied 12 patients who had incomplete colonoscopy -- 6 patients had an obstructing tumor of the left side of the colon; and in 6 cases, there were technical difficulties to complete colonoscopy. PillCam colon capsule endoscopy visualized the rectum in 1 case. The capsule did not reach the site where colonoscopy stopped in 6 of the 12 cases, i.e., 3 left sited tumors and 3 with technical difficulties. Moreover, in 1 of the 3 cases in which the capsule passed the site where colonoscopy stopped, poor bowel preparation precluded the accurate examination of the colon. Four patients underwent a third colon examination (3 barium enemas and 1 virtual CT colonoscopy). There were no adverse events related to PCC endoscopy. The authors concluded that in this retrospective case series of patients with incomplete colonoscopy, PCC endoscopy did not always satisfactorily examine the colon.

In a meta-analysis evaluating the accuracy of CCE in detecting colon polyps, Rokkas et al (2010) concluded that CCE is a feasible alternative method for colon investigation, including screening for polyps and CRC, patients with incomplete colonoscopy, those with contraindications for conventional colonoscopy, or those unwilling to undergo colonoscopy because of its perceived inconvenience and discomfort. They stated that however, larger, multi-center, well-designed trials are needed to further establish the role of CCE in the evaluation of the large bowel in health and disease.

Spada et al (2010) noted that the PillCam colon capsule endoscopy (PCCE) represents one of the newest diagnostic, endoscopic technology designed to explore the colon. It is a non-invasive, swallowing colonoscope that is able to explore the colon without requiring sedation, nor radiation. The colon capsule measures 31 mm x 11 mm. It has dual cameras that enable to take pictures from both ends at a frame rate of 4 frames per second. The goal of PCCE is to substitute the conventional colonoscopy in the diagnosis of colonic diseases and to discriminate patients who deserve a conventional colonoscopy. The authors stated that although the preliminary results available in literature are encouraging, further studies are needed to confirm and increase the accuracy parameters and to select a more tolerable and effective regimen of preparation. In a review on alternatives to colonoscopy and their limitations, Chaput and co-workers (2010) stated that the PillCam for the small intestine has been adapted to study of the colon. Results of CCE studies are promising.

Capsule endoscopy is contraindicated in patients with known or suspected gastrointestinal obstruction, strictures, or fistulae. The available literature indicates that an upper gastrointestinal series should be performed prior to capsule endoscopy if the patient is suspected of having intestinal obstruction. In a review on contraindications to capsule endoscopy, Storch and Barkin (2006) stated that the only true remaining contraindications to capsule endoscopy are obstruction/pseudo-obstruction and pregnancy.

The Agile Patency System (Given Imaging, Ltd.) was cleared by the FDA through the 510k process for determining the presence of obstructions or strictures in the gastrointestinal tract through a dissolvable capsule. It supposedly will give physicians confidence that a PillCam video capsule will pass freely in a patient with known or suspected strictures. suspected strictures. Currently, there is insufficient evidence on the performance of this patency system as a technique to evaluate patients with known or suspected strictures prior to using the wireless capsule endoscopy system.

Spada et al (2007) evaluated the safety of the Pillcam in patients with known or suspected radiological stricture, previously tested for small bowel patency using the Given Patency capsule. A total of 27 patients (16 females, mean age of 44.2 years) with known or suspected intestinal stricture were enrolled prospectively: 24 had Crohn's disease, 2 had adhesive syndrome, and 1 had a suspected ischemic stricture. Patients underwent the Patency capsule test. In patients in whom the Patency capsule was excreted intact within 72 hours post-ingestion without occurrence of any adverse event, video capsule endoscopy (VCE) was performed to assess the presence of strictures or other gastrointestinal pathologies. The following parameters were evaluated: transit time of Patency capsules and/or tags from ingestion to excretion, condition of the Patency capsule at excretion, transit time of the Pillcam capsule, the ability of Pillcam capsule to detect intestinal strictures and small bowel pathologies, any adverse events. A total of 25 patients (92.6 %) retrieved the Patency capsule in the stools; 6 patients complained of abdominal pain, 4 of whom excreted a non-intact capsule. Hospitalization was required in 1 (4.3 %) patient with Crohn's disease due to occlusive syndrome. Fifteen patients (65.3 %) excreted an intact Patency capsule after a mean transit time of 25.6 hours without any adverse events. These 15 patients underwent the VCE successfully. The authors concluded that passage of an intact Patency capsule across a small bowel stricture provides direct evidence of functional patency of the gut lumen and allows a safe VCE. Intestinal strictures should not be considered an absolute contraindication for VCE.

Herrerias and colleagues (2008) assessed the ability of the Agile Patency System to help physicians identify which patients with known strictures may safely undergo CE. A total of 106 patients ingested the patency capsule. Fifty-nine (56 %) excreted it intact and subsequently underwent CE. There were no cases of capsule retention. Significant findings on CE were found in 24 (41 %). There were 3 severe adverse events. The authors concluded that these findings suggested that the Agile Patency System is a useful tool for physicians to use before CE in patients with strictures to avoid retention. This group of patients may have a high yield of clinically significant findings at CE. This capsule may determine whether patients who have a contraindication to CE may safely undergo CE and obtain useful diagnostic information.

The Agile Patency System has been reported to cause obstruction requiring urgent intervention. There is currently insufficient evidence from well-designed studies to support the use of the Agile Patency System. In addition, the American Society for Gastrointestinal Endoscopy's Technology Status Evaluation Report on wireless capsule endoscopy (Mishkin et al, 2006) stated that "[t]here is limited information about the new patency capsule. While it is intended to assess the passage of a capsule in patients at risk for intestinal stenosis, there have been reported cases that have required hospital admissions, augmentation of medical therapy, and even surgery. As a result, improvements to the system are being implemented before it can be approved in the United States".

In a randomized, controlled trial, Keller and colleagues (2010) assessed the safety and effectiveness of remote magnetic manipulation of a modified capsule endoscope (magnetic maneuverable capsule [MMC]; Given Imaging Ltd, Yoqneam, Israel) in the esophagus of healthy humans. A total of 10 healthy volunteers swallowed a conventional capsule (ESO2; Given Imaging) and a capsule endoscope with magnetic material, the MMC, which is activated by a thermal switch, in random order (1 week apart). An external magnetic paddle (EMP; Given Imaging) was used to manipulate the MMC within the esophageal lumen. MMC responsiveness was evaluated on a screen showing the MMC film in real time. Main outcome measurements included safety and tolerability of the procedure (questionnaire), responsiveness of the MMC to the EMP, esophageal transit time, and visualization of the Z-line. No adverse events occurred apart from mild retro-sternal pressure (n = 5). The ability to rotate the MMC around its longitudinal axis and to tilt it by defined movements of the EMP was clearly demonstrated in 9 volunteers. Esophageal transit time was highly variable for both capsules (MMC, 111 to 1,514 seconds; ESO2, 47 to 1,474 seconds), but the MMC stayed longer in the esophagus in 8 participants (p < 0.01). Visualization of the Z-line was more efficient with the ESO2 (inspection of 73 % +/- 18 % of the circumference versus 33 % +/- 27 %, p = 0.01). The authors concluded that remote control of the MMC in the esophagus of healthy volunteers is safe and feasible, but higher magnetic forces may be needed.

In an open clinical trial, Keller et al (2011) evaluated the safety and effectiveness of manipulation of a MMC in the human stomach by using a hand-held external magnet. A total of 10 healthy volunteers swallowed the MMC and sherbet powder for gastric distention. An EMP-2 was used to manipulate the MMC within the stomach. Responsiveness of the MMC was evaluated on a screen showing the MMC film in real time. Main outcome measurements included safety and tolerability (questionnaire), gastric residence time of the MMC, its responsiveness to the EMP-2, and visualization of gastric mucosa. There were no adverse events. The MMC was always clearly attracted by the EMP-2 and responded to its movements. It remained in the stomach for 39 +/- 24 minutes. In 7 subjects, both the cardia and the pylorus were inspected and 75 % or more of the gastric mucosa was visualized (greater than or equal to 50 % in all of the remaining subjects). A learning curve was clearly recognizable (identification of MMC localization, intended movements). The authors concluded that remote control of the MMC in the stomach of healthy volunteers using a hand-held magnet is safe and feasible. Responsiveness of the MMC was excellent, and visualization of the gastric mucosa was good, although not yet complete, in the majority of subjects. They stated that the system appeared to be clinically valuable and should be developed further.

Gastineau and colleagues (2012) evaluated the contribution of CE in managing risk of further obstructive complications.  These researchers performed a retrospective analysis of 27 children who received at least 1 capsule endoscopy.  Peutz-Jeghers syndrome was diagnosed based on the presence of an STK11 gene mutation or on the association of a hamartoma with 2 of 3 criteria (family history, mucocutaneous pigmentation, small bowel polyposis).  A total of 37 CEs were performed in 27 patients.  The median age at first endoscopy was 11.4 years (range of 5.4 to 20.9).  Jejunal polyps were found in 72 % and ileal polyps in 55 % of capsules.  The original recommendations were followed 20/30 times.  Three gastroscopies, 4 colonoscopies, 7 double balloon enteroscopies and 1 intra-operative enteroscopy were performed after the capsules.  These procedures revealed jejunal polyps in 9/9 cases (8/9 resected) and ileal polyps in 3/5 (all resected).  One intussusception occurred 8.4 months after the CE and required surgical resection.  The authors concluded that CE is easily feasible in Peutz Jeghers syndrome, but the practice of systematic and repeated procedures needs to be validated prospectively.

Minaya et al (2012) stated that intussusception in adult patients accounted for less than 5 % of all intussusceptions. It occurs when a segment of intestine invaginates into itself.  These investigators reported a case of ileo-colic intussusception in an adult caused by a giant ileal lipoma.  Intussusceptions can be classified as ileo-colic, ileo-cecal, colo-colic and ileo-ileal.  Most are due to neoplasms (60 % malign and 24 to 40 % benign).  In the colon, the possibility of malignancy is higher than in small intestine.  Lipomas are the most common benign mesenchymal intestinal tumors, accounting for less than 5 % of all gastro-intestinal tumors.  They are more frequent in colon than small intestine.  Small lipomas (less than 2 cm) are usually asymptomatic.  Larger lesions may produce symptoms such as abdominal pain, obstruction or intussusception.  Lipomas can be diagnosed with endoscopy, CE, barium enemas, CT and ultrasonography.  The authors concluded that intussusceptions in adults is a rare condition, most of them are caused by a malign neoplasms followed by benign neoplasms; CT and ultrasonography are useful for diagnosis.  Capsule endoscopy was not mentioned as a management tool.

Wiener-Carrillo et al (2014) noted that intussusception in adult patients represented 5 % of all intussusceptions and 1 to 5% of bowel obstructions in adults.  In contrast to pediatric patients, 90 % of the time, in adults, it's caused by well-established pathologic mechanisms, such as carcinoma, polyps, diverticula, Meckel diverticula, stenosis, or benign neoplasms.  Small intestine intussusceptions are more frequent, but colonic intussusceptions are caused 50 % of the time by malignant neoplasms, especially adenocarcinoma.  These investigators presented the case of a 70-year old woman, with no relevant familial history, who presented with a 3-day symptomatology consisting of epigastric, colic, diffuse, abdominal pain of moderate intensity, which progressed till reaching a severe intensity, also referring abdominal distension, nausea, and gastrointestinal-content vomits.  In adult patients, the exact mechanism of intussusception is unknown in 8 to 20 % of the cases, however, secondary intussusception can occur with any lesion of the intestinal wall or any irritant factor in its lumen that alters normal peristaltic activity and that could serve as a trigger to start an intussusception of one bowel segment over another the most common site is the small intestine.  The authors concluded that intussusception represents an unusual problem in adult patients; it requires a high clinical suspicion, mainly as a differential diagnosis in patients with intestinal obstruction, and it clinically presents as a subacute or chronic illness.  They stated that CT represents the most useful diagnostic tool.  Capsule endoscopy was not mentioned as a management tool.

The American College of Radiology’s clinical practice guideline on “Suspected small-bowel obstruction” (Katz et al, 2013) noted that ultrasonography has proven useful in evaluating intussusception, mid-gut volvulus, and other causes of suspected small-bowel obstruction.  Moreover, CE was not mentioned as a management tool.  Furthermore, an UpToDate reviews on “Intussusception in children” (Kitagawa and Miqdady, 2014) and “Epidemiology, clinical features, and diagnosis of mechanical small bowel obstruction in adults” (Bordeianou and Yeh, 2014) do not mention the use of capsule endoscopy as a management tool.

Xue et al (2015) evaluated the diagnostic yield of small-bowel CE (SBCE) in patients with unexplained chronic abdominal pain.  These investigators performed a retrospective review of publications reporting the diagnostic yield of SBCE in patients with unexplained chronic abdominal pain and calculated the overall diagnostic yield (DY).  Two investigators independently searched studies from databases and analyzed the results.  A total of 1,520 patients from 21 studies were included.  Per-patient DY, with 95 % CI, was evaluated by a random-effect model.  Clear categorical analysis also was performed.  The pooled DY of SBCE in patients with unexplained chronic abdominal pain was 20.9 % (95 % CI: 15.9 % to 25.9 %), with high heterogeneity (I(2) = 80.0 %; p < 0.001).  Inflammatory lesions were the most common (78.3 %) positive findings, followed by tumors (9.0 %).  The authors concluded that SBCE provided a non-invasive diagnostic tool for patients with unexplained chronic abdominal pain, but the DY was limited (20.9 %).

On behalf of the European Society of Gastrointestinal Endoscopy (ESGE), Pennazio et al (2015) addressed the roles of small-bowel CE and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders.  One of the main recommendations was that ESGE strongly recommends against the use of small-bowel CE for suspected celiac disease; but suggests that CE could be used in patients unwilling or unable to undergo conventional endoscopy (strong recommendation, low quality evidence). 

Frennette and colleagues (2009) examined the utility of ECE in the diagnosis and grading of esophageal varices.  Cirrhotic patients who were undergoing EGD for variceal screening or surveillance underwent CE.  Two separate blinded investigators read each CE for the following results: variceal grade, need for treatment with variceal banding or prophylaxis with beta-blocker therapy, degree of portal hypertensive gastropathy, and gastric varices.  A total of 50 patients underwent both capsule and EGD; 48 had both procedures on the same day, and 2 patients had CE within 72 hrs of EGD.  The accuracy of CE to decide on the need for prophylaxis was 74 %, with sensitivity of 63 % and specificity of 82 %.  Inter-rater agreement was moderate (kappa = 0.56).  Agreement between EGD and CE on grade of varices was 0.53 (moderate).  Inter-rater reliability was good (kappa = 0.77).  In diagnosis of portal hypertensive gastropathy, accuracy was 57 %, with sensitivity of 96 % and specificity of 17 %.  Two patients had gastric varices seen on EGD, 1 of which was seen on CE.  There were no complications from CE.  The authors concluded that CE has a limited role in deciding which patients would benefit from EGD with banding or beta-blocker therapy.  They stated that more research is needed to assess accuracy for staging esophageal varices, portal hypertensive gastropathy, and the detection of gastric varices.

In a Cochrane review, Colli et al (2014) stated that current guidelines recommend performance of EGD at the time of diagnosis of hepatic cirrhosis to screen for esophageal varices.  These guidelines require people to undergo an unpleasant invasive procedure repeatedly with its attendant risks, despite the fact that 50 % of the people do not have identifiable esophageal varices 10 years after the initial diagnosis of cirrhosis.  Video CE is a non-invasive test proposed as an alternative method for the diagnosis of esophageal varices.  These investigators determined the diagnostic accuracy of CE for the diagnosis of esophageal varices in children or adults with chronic liver disease or portal vein thrombosis, irrespective of the etiology.  They investigated the accuracy of CE as triage or replacement of EGD.  These investigators searched the Cochrane Hepato-Biliary Group Diagnostic Test Accuracy Studies Register (October 2013), MEDLINE (Ovid SP) (1950 to October 2013), EMBASE (Ovid SP) (1980 to October 2013), ACP Journal Club (Ovid SP) (1991 to October 2013), Database of Abstracts of Reviews of Effects (DARE) (Ovid SP) (3rd quarter), Health Technology Assessment (HTA) (Ovid SP) (3rd quarter), NHS Economic Evaluation Database (NHSEED) (Ovid SP) (3rd quarter), and Science Citation Index Expanded (SCI-EXPANDED) (ISI Web of Knowledge) (1955 to October 2013).  They applied no language or document type restrictions.  Studies that evaluated the diagnostic accuracy of CE for the diagnosis of esophageal varices using EGD as the reference standard in children or adults of any age, with chronic liver disease or portal vein thrombosis were selected for analysis.  These researchers followed the available guidelines provided in the Cochrane Handbook for Diagnostic Test of Accuracy Reviews.  They calculated the pooled estimates of sensitivity and specificity using the bi-variate model due to the absence of a negative correlation in the receiver operating characteristic (ROC) space and of a threshold effect.  The search identified 16 eligible studies, in which only adults with cirrhosis were included.  In 1 study, people with portal thrombosis were also included.  The authors classified most of the studies at high risk of bias for the 'Participants selection' and the 'Flow and timing' domains.  One study assessed the accuracy of CE for the diagnosis of large (high-risk) esophageal varices.  In the remaining 15 studies that assessed the accuracy of CE for the diagnosis of esophageal varices of any size in people with cirrhosis, 936 participants were included; the pooled estimate of sensitivity was 84.8 % (95 % CI: 77.3 % to 90.2 %) and of specificity 84.3 % (95 % CI: 73.1 % to 91.4 %).  Eight of these studies included people with suspected varices or people with already diagnosed or even treated varices, or both, introducing a selection bias.  Seven studies including only people with suspected but unknown varices were at low risk of bias; the pooled estimate of sensitivity was 79.7 % (95 % CI: 73.1 % to 85.0 %) and of specificity 86.1 % (95 % CI: 64.5 % to 95.5 %).  Six studies assessed the diagnostic accuracy of CE for the diagnosis of large esophageal varices, associated with a higher risk of bleeding; the pooled sensitivity was 73.7 % (95 % CI: 52.4 % to 87.7 %) and of specificity 90.5 % (95 % CI: 84.1 % to 94.4 %).  Two studies also evaluated the presence of red marks, which are another marker of high risk of bleeding; the estimates of sensitivity and specificity varied widely.  Two studies obtained similar results with the use of a modified device as index test (string capsule).  Due to the absence of data, these researchers could not perform all planned subgroup analyses.  Inter-observer agreement in the interpretation of CE results and any adverse event attributable to CE were poorly assessed and reported.  Only 4 studies evaluated the inter-observer agreement in the interpretation of CE results: the concordance was moderate.  The participants' preferences for CE or EGD were reported differently but seemed in favor of CE in 9 of 10 studies.  In 10 studies, participants reported some minor discomfort on swallowing the capsule.  Only 1 study identified other significant adverse events, including impaction of the capsule due to previously unidentified esophageal strictures in 2 participants.  No adverse events were reported as a consequence of the reference standard.  The authors concluded that they cannot support the use of CE as a triage test in adults with cirrhosis, administered before EGD, despite the low incidence of adverse events and participant reports of being better-tolerated.  Thus, they stated that that EGD cannot be replaced by CE for the detection of esophageal varices in adults with cirrhosis.  Moreover, they found no data assessing CE in children and in people with portal thrombosis.

In an evidence-based analysis, Health Quality Ontario (2015) evaluated the diagnostic accuracy and safety of CCE for the detection of colorectal polyps among adult patients with signs or symptoms of CRC or with increased risk of CRC, and compared CCE with alternative procedures. They performed a literature search using Ovid Medline, Ovid Medline In-Process and Other Non-Indexed Citations, Ovid Embase, the Wiley Cochrane Library, and the Centre for Reviews and Dissemination database, for studies published between 2006 and 2014.  Data on diagnostic accuracy and safety were abstracted from included studies.  Quality of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE).  The search yielded 2,189 citations; 5 studies, all of which evaluated PillCam COLON 2 (PCC2), met the inclusion criteria.  The per-patient sensitivity and specificity for detecting colorectal polyps were meta-analyzed.  Colon capsule endoscopy, using PCC2, had a pooled sensitivity and specificity of 87 % (95 % CI: 77 % to 93 %) and 76 % (95 % CI: 60 % to 87 %), respectively, for the detection of a colorectal polyp at least 6-mm in size (GRADE: very low).  PCC2 had a pooled sensitivity and specificity of 89 % (95 % CI: 77 % to 95 %) and 91 % (95 % CI: 86 % to 95 %), respectively, for the detection of a colorectal polyp at least 10-mm in size (GRADE: low).  One study directly compared PCC2 with CT colonography and found no statistically significant difference in accuracy (GRADE: low).  Few adverse events were reported with PCC2; 3.9 % of patients (95 % CI: 2.4 % to 6.5 %) experienced adverse effects related to bowel preparation.  Capsule retention was the most serious adverse event and occurred in 0.8 % of patients (95 % CI: 0.2 % to 2.4 %) (GRADE: very low).  The authors concluded that in adult patients with signs, symptoms, or increased risk of CRC, there is low-quality evidence that CCE using the PCC2 device has good sensitivity and specificity for detecting colorectal polyps.  They stated that low-quality evidence does not show a difference in accuracy between CCE and CT colonography; and there is very low-quality evidence that PCC2 has a good safety profile with few adverse events; capsule retention is the most serious complication.

Chronic Kidney Disease

Docherty et al (2015) stated that there are only few reports on the DY of SBCE in patients with chronic kidney disease (CKD).  In a retrospective study, these investigators reported their SBCE experience in patients with CKD.  Case notes of patients with low estimated glomerular filtration rate (eGFR) who underwent SBCE (March 2005 to August 2012) for anemia and/or OGIB were retrieved and abstracted.  Severity of CKD was defined according to Renal Association recommendations as: Stage 3 (eGFR: 30 to 59); Stage 4 (eGFR: 15 to 29); and Stage 5 (eGFR less than 15 or on dialysis).  In the afore-mentioned period, 69 patients with CKD [Stage 3: 65/69 (92.8 %), Stage 4 or 5:4/69 (7.2 %)] had SBCE; 51/65 (78.5 %) patients with Stage 3 CKD had SBCE due to unexplained anemia and/or OGIB [43 (66.1 %) and 8 (12.3 %), respectively].  In 25/51 (49 %), the SBCE was normal and in 17/51 (33.3 %) showed small-bowel angiectasias.  Other findings were active bleeding (n = 2), fold edema (n = 2), ileal erosions (n = 1), adenocarcinoma (n = 1), and inconclusive/videos not available (n = 3).  All patients (n = 4) with CKD Stage 4 or 5 were referred due to unexplained anemia; 3/4 (75 %) had angiectasias and 1 normal SBCE.  Fecal calprotectin (FC) was measured in 12 patients with CKD Stage 3 and unexplained anemia prior to their SBCE; no significant small-bowel inflammation was found in this subgroup.  The authors concluded that SBCE has limited DY in CKD patients referred for unexplained anemia.  Sinister SB pathology is rare, while the most common finding is angiectasias.  Furthermore, FC measurement prior to SBCE -- in this cohort of patients -- is not associated with increased DY.

Evaluation of Mucosal Inflammation in Ulcerative Colitis

Shi and colleagues (2015) stated that evaluation of mucosal inflammation is important in the management of patients with ulcerative colitis (UC). Colon capsule endoscopy has recently been shown to be effective in colorectal polyp detection.  However, its role in the evaluation of mucosal inflammation in UC is unclear.  This systematic review aimed to clarify the state of the art with an evidence-based summary of current studies on the utility of CCE in UC.  The overall results showed that the accuracy of CCE for assessment of mucosal inflammation in UC appeared to be comparable with that of colonoscopy.  Moreover, the authors stated that long-term follow-up studies with larger sample size are needed to further validate the utility of CCE in the management of UC subjects in clinical practice.

Furthermore, UpToDate reviews on “Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults” (Peppercorn and Kane, 2016), “Management of mild to moderate ulcerative colitis in adults” (MacDermott, 2016), and “Management of severe ulcerative colitis in adults” (Peppercorn and Farrell, 2016) do not mention capsule endoscopy as a management tool.

Fecal Occult Blood Testing (FOBT) as a Screening Tool for Small-Bowel Capsule Endoscopy

Yung and colleagues (2017) noted that fecal occult blood testing (FOBT) has been suggested as a potential screening tool for small-bowel CE.  These researchers conducted a meta-analysis of studies correlating FOBT and CE findings to examine the predictive value of positive FOBT for CE findings.  PubMed and Embase searches were carried out; sensitivity, specificity and diagnostic odds ratios (DORs) were calculated.  A total of 6 studies were identified; 4 used fecal immunochemical testing (FIT), 1 used FIT and guaiac FOBT, 1 used hemoglobin/haptoglobin complex testing (Hb/Hpt); 5 of the 6 studies were suitable for statistical analysis.  For all positive FOBT, sensitivity for small-bowel findings was 0.60 (95 % CI: 0.50 to 0.69), specificity was 0.72 (95 % CI: 0.52 to 0.86), and DOR was 3.96 (95 % CI: 1.50 to 10.4).  For the 4 studies using only FIT, sensitivity was 0.48 (95 % CI: 0.36 to 0.61), specificity was 0.60 (95 % CI: 0.42 to 0.76), and DOR was 1.41 (95 % CI: 0.72 to 2.75).  The authors concluded that although a number of modalities have been suggested for screening small-bowel CE referrals, none of them, including FOBT, offered a comprehensive solution.  They stated that further investigation is needed to refine screening methods (e.g., combining other fecal or serum markers) for the selection of patients for small-bowel CE.

Detection of Hookworm

He and co-workers (2018) noted that as one of the most common human helminths, hookworm is a leading cause of maternal and child morbidity, which seriously threatens human health.  Recently, wireless capsule endoscopy (WCE) has been applied to automatic hookworm detection.  Unfortunately, it remains a challenging task.  In recent years, deep convolutional neural network (CNN) has demonstrated impressive performance in various image and video analysis tasks.  In this paper, a novel deep hookworm detection framework is proposed for WCE images, which simultaneously models visual appearances and tubular patterns of hookworms.  This was the 1st deep learning framework specifically designed for hookworm detection in WCE images.  Two CNN networks, namely edge extraction network and hookworm classification network, were integrated in the proposed framework, which avoided the edge feature caching and sped up the classification.  Two edge pooling layers were introduced to integrate the tubular regions induced from edge extraction network and the feature maps from hookworm classification network, leading to enhanced feature maps emphasizing the tubular regions.  Experiments have been conducted on one of the largest WCE datasets with WCE images, which demonstrated the effectiveness of the proposed hookworm detection framework.  It significantly out-performed the state-of-the-art approaches.  The authors concluded that the high sensitivity and accuracy of the proposed method in detecting hookworms showed its potential for clinical application.

Diagnosis of Iron Deficiency Anemia

Yung and colleagues (2017) stated that recent data implied young patients (aged less than or equal to 50 years) undergoing SBCE for iron deficiency anemia (IDA) showed higher diagnostic yield (DY) for sinister pathology. In  a retrospective, multi-center study (2010-2015), these investigators examined DY of CE in a large cohort of young IDA patients, and evaluated factors predicting significant SB pathology.  Consecutive, young patients from 18 centers/12 countries, with negative bi-directional GI endoscopy undergoing SBCE for IDA were included in this analysis.  Exclusion criteria: previous/ongoing obscure-overt GI bleeding; age of less than 19 or greater than 50 years; co-morbidities associated with IDA.  Data retrieved: SBCE indications; prior investigations; medications; SBCE findings; final diagnosis.  Clinical and laboratory data were analyzed by multi-variate logistic regression.  Data on 389 young IDA patients were retrieved.  In total, 169 (43.4 %) were excluded due to incomplete clinical data; data from 220 (122 women/98 men; mean age of 40.5 ± 8.6 years) patients were analyzed.  Some 71 patients had at least 1 clinically significant SBCE finding (DY: 32.3 %).  They were divided into 2 groups: neoplastic pathology (10/220; 4.5 %), and non-neoplastic but clinically significant pathology (61/220; 27.7 %).  The most common significant but non-neoplastic pathologies were angioectasias (22/61) and CD (15/61).  On multi-variate analysis, weight loss and lower mean corpuscular volume(MCV) were associated with significant SB pathology (OR: 3.87; 95 % CI: 1.3 to 11.3; p = 0.01; and OR: 0.96; 95 % CI: 0.92 to 0.99; p = 0.03; respectively).  The model also demonstrated association between use of anti-platelets and significant SB pathology, although due to the small number of patients, definitive conclusions could not be drawn.  The author concluded that in IDA patients less than or equal to 50 years with negative bi-directional GI endoscopy, overall DY of SBCE for clinically significant findings was 32.3 %.  Some 5 % of this cohort was diagnosed with SB neoplasia; lower MCV or weight loss were associated with higher DY for SB pathology.

The authors stated that drawbacks of this study included its retrospective study design, meaning that clinical data were incomplete for several patients (almost 50 % in this cohort).  This could have led to some over-estimation of these findings.  These researchers have attempted to minimize this possible effect using multi-variate analysis as detailed.  Secondly, many of our centers were high-volume or tertiary referral centers, which would therefore have taken a disproportionate number of complex patients or those suspected of having sinister pathology.  Finally, this study used MCV as a marker of iron deficiency in anemic patients, although limitations exist to the use of MCV to quantify iron deficiency.  Other red cell indices such as mean cell hemoglobin (MCH) (i.e. markers of hypochromia rather than microcytosis) may correlate better with severity of IDA than MCV.  Current guidelines state that MCV alone is not enough to make a diagnosis of IDA and other parameters, namely ferritin, should be used to assess iron status, as ferritin correlates well with total body iron stores and is a better marker of iron deficiency; low MCV occurs only in the later stages of iron deficiency.  Data on ferritin were not available for all the patients in this cohort, and MCV was used in this study due to its widespread use and availability.  Both markers are less reliable in elderly and/or hospitalized patient populations, and in several other co-morbidities (e.g., inflammation and anemia of chronic disease) but may be more reliable in the younger group that overall has a lower rate of co-morbidities.

Diagnosis of Takayasu’s Arteritis

Olano and Cohen (2018) reported the case of an asymptomatic 62-year old woman who presented for a routine annual examination and was found to have elevated sedimentation rate and C-reactive protein (CRP).  Physical examination was normal except for a difference in blood pressure between arms (120/74 on the right and 110/76 on the left); CT scan demonstrated an aortitis, and positron emission tomography (PET)-CT scan confirmed the presence of active inflammatory disease.  She received prednisone 40 mg daily for 30 days, but discontinued the treatment because of multiple side effects.  One year later, the patient presented with severe intermittent abdominal pain, which was worst when lying flat.  She had anorexia and lost several pounds.  Results from ultrasonography and basic laboratory studies were unremarkable other than elevation of acute phase reactants and anemia.  Upper GI endoscopy revealed gastritis.  Colonoscopy showed patchy submucosal hemorrhagic lesions in the right colon.  Capsule endoscopy showed diffuse and continuous involvement of the jejunal mucosa, with edema, reddish patches, and erosions.  Ischemic manifestation of a large vessel vasculitis (Takayasu’s arteritis) was suspected.  The authors stated that to their knowledge, this was the first report of Takayasu’s arteritis diagnosed by video capsule endoscopy.

An UpToDate review on “Clinical features and diagnosis of Takayasu arteritis” (Merkel, 2018) does not mention capsule endoscopy as a diagnostic tool.

Table: CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
CPT codes covered if selection criteria are met:
91110	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus through ileum, with physician interpretation and report
91111	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with physician interpretation and report
CPT codes not covered for indications listed in the CPB:
0355T	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report
Other CPT codes related to the CPB:
77261 - 77263	Therapeutic radiology treatment planning
77299	Unlisted procedure, therapeutic radiology clinical treatment planning
ICD-10 codes covered if selection criteria are met (for capsule endoscopy - esophagus through ileum):
C7a.010 - C7a.019	Malignant carcinoid tumors of the small intestine
D3a.010 - D3a.019	Benign carcinoid tumors of the small intestine
D50.0	Iron deficiency anemia secondary to blood loss (chronic)
D50.9	Iron deficiency anemia, unspecified
D62	Acute posthemorrhagic anemia
D72.89	Other specified disorders of white blood cells
K50.00 - K50.919	Crohn's disease [regional enteritis]
K52.0 - K52.9	Other and unspecified noninfectious gastroenteritis and colitis
K90.0	Celiac disease
K92.0 - K92.2	Other diseases of digestive system
R10.0 - R10.33 R10.84 - R10.9	Abdominal pain
R19.7	Diarrhea
R50.81	Fever presenting with conditions classified elsewhere
R50.9	Fever, unspecified
R63.4	Abnormal loss of weight
R70.0	Elevated erythrocyte sedimentation rate
Z09	Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm [reevaluation of celiac disease]
ICD-10 codes covered if selection criteria are met (for capsule endoscopy - esophagus only):
I85.00 - I85.01	Esophageal varices with bleeding or without bleeding
I85.11	Secondary esophageal varices with bleeding
K70.2 - K70.31	Alcoholic cirrhosis of liver
K74.0	Hepatic fibrosis
K74.3 - K74.5	Biliary cirrhosis
K74.60 - K74.69	Other and unspecified cirrhosis of liver
Z09	Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm [reevaluation of celiac disease]
Z15.09	Genetic susceptibility to other malignant neoplasm [Lynch syndrome]
ICD-10 codes not covered for indications listed in the CPB (not all inclusive):
B76.0 - B76.9	Hookworm disease
C15.3 - C15.9	Malignant neoplasm of esophagus
C17.0 - C17.9	Malignant neoplasm of small intestine, including duodenum, and colon
C7A.010 - C7A.019	Malignant carcinoid tumors of the small intestine
C7A.020 - C7A.029	Malignant neoplasm of the appendix, large intestine, and rectum
D12.0 - D12.9	Benign neoplasm of colon
D3A.020 - D3A.029	Benign carcinoid tumors of the appendix, large intestine, and rectum
D72.820	Lymphocytosis (symptomatic) [duodenal lymphocytosis]
I86.4	Gastric varices
K22.0 - K22.9	Other diseases of esophagus
K31.2	Hourglass stricture and stenosis of stomach
K31.6	Fistula of stomach and duodenum
K31.89	Other diseases of stomach and duodenum [Portal hypertensive gastropathy]
K51.00 - K51.919	Ulcerative colitis
K56.0 - K56.7	Paralytic ileus and intestinal obstruction without hernia [intussception]
K57.20 - K57.93	Diverticular disease of colon
K58.0 - K58.9	Irritable bowel syndrome
K59.01	Slow transit constipation
K59.31 - K59.39	Megacolon, not elsewhere classified
K59.8	Other specified functional intestinal disorders
K63.2	Fistula of intestine
K63.5	Polyp of colon
K90.0	Celiac disease
M31.4	Aortic arch syndrome [Takayasu]
Q39.5	Congenital dilatation of esophagus
Q40.2 - Q40.3	Other and unspecified congenital malformations of stomach
Q41.0 - Q42.9	Congenital absence, atresia and stenosis of small intestine and large intestine
Q43.4 - Q43.9	Other congenital malformations of intestine [recurrent intussusception]
R13.10 - R13.19	Dysphagia
Z12.10 - Z12.13	Encounter for screening for malignant neoplasm of intestine
Z95.0	Presence of cardiac pacemaker
Z96.89	Presence of other specified functional implants [electromedical devices]

The above policy is based on the following references: